secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2022-08-05T23:59:59+00:00
Accession:  0000320017-22-000061
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caladrius Q2 net loss $6.6M; merger with Cend on track for Q3 2022 forming Lisata Therapeutics
--------------------------------------------------------------------------------

- Net loss $6.6M vs $5.7M YoY; cash $73M after $10M Cend investment.
- Merger with Cend expected to close Q3 2022, pending stockholder approval; new ticker LSTA.
- HONEDRA pre-consultation with PMDA; XOWNA FREEDOM trial enrollment suspended, interim analysis in Q3.
- CLBS201 DKD trial fully enrolled (6 patients), top-line data expected Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000061/0000320017-22-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000061/clbs-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000320017-22-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer